Natera develops molecular diagnostic tests based on cell-free DNA and genomic analysis. Its commercial tests cover noninvasive prenatal screening, transplant organ rejection monitoring, and oncology minimal residual disease detection, including the Signatera platform. Revenue depends on testing volumes, reimbursement, and adoption by physicians, health systems, and patients.
Natera Inc. (NTRA) has a MarketKingdoms composite score of 68.5 (B), an B-range rating. It ranks 455th of 1,866 covered companies, 19th of 78 in Healthcare (sector average 64.4) and 7th of 13 in Diagnostics & Research. Scores as of 2026-10-26.
Its strongest lenses are KPI momentum at 93 (Healthcare average 78) and Expansion (growth) at 93 (Healthcare average 50). Its weakest lenses are Price (valuation) at 6 (sector average 50) and Quality (profitability) at 16 (sector average 50).
| Lens | Type | NTRA | Healthcare average | Diagnostics & Research average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 90 | 81 | 90 | 95th |
| Stock selection | Research signal | 87 | 79 | 83 | 97th |
| KPI momentum | Research signal | 93 | 78 | 85 | 94th |
| Catalyst watch | Research signal | 77 | 74 | 77 | 72nd |
| Price (valuation) | Fundamental lens | 6 | 50 | 32 | 4th |
| Expansion (growth) | Fundamental lens | 93 | 50 | 52 | 97th |
| Quality (profitability) | Fundamental lens | 16 | 50 | 42 | 5th |
| Trend (momentum) | Fundamental lens | 88 | 50 | 69 | 97th |
The most recent call analysed was held on 2026-08-06 (fiscal 2026 Q2). MarketKingdoms checks what management promised on each call against what it later delivered.
The stock's valuation gap is -22.9%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 2.19, sector beta 0.50, industry beta 0.76; the factor model explains 24% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Illumina Inc. (ILMN) | 71.2 | B+ | +22.1% |
| Agilent Technologies Inc. (A) | 69.3 | B | -3.1% |
| Quest Diagnostics Incorporated (DGX) | 69.2 | B | -4.1% |
| Revvity Inc. (RVTY) | 69.2 | B | +8.2% |
| IQVIA Holdings Inc. (IQV) | 68.9 | B | -16.5% |
| Labcorp Holdings Inc. (LH) | 68.9 | B | -13.5% |
| Charles River Laboratories International Inc. (CRL) | 68.2 | B | -15.8% |
| Waters Corp. (WAT) | 68.0 | B | -6.2% |
Natera Inc. financial statements · Healthcare sector ranking · Diagnostics & Research industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.